BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 37569509)

  • 1. Novel Matrix Metalloproteinase-9 (MMP-9) Inhibitors in Cancer Treatment.
    Rashid ZA; Bardaweel SK
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview.
    Mondal S; Adhikari N; Banerjee S; Amin SA; Jha T
    Eur J Med Chem; 2020 May; 194():112260. PubMed ID: 32224379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiological Properties, Functions, and Trends in the Matrix Metalloproteinase Inhibitors in Inflammation-Mediated Human Diseases.
    Kim IS; Yang WS; Kim CH
    Curr Med Chem; 2023; 30(18):2075-2112. PubMed ID: 36017851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next generation matrix metalloproteinase inhibitors - Novel strategies bring new prospects.
    Levin M; Udi Y; Solomonov I; Sagi I
    Biochim Biophys Acta Mol Cell Res; 2017 Nov; 1864(11 Pt A):1927-1939. PubMed ID: 28636874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of gelatinases (MMP-2 and MMP-9) for the management of hematological malignancies.
    Das S; Amin SA; Jha T
    Eur J Med Chem; 2021 Nov; 223():113623. PubMed ID: 34157437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metalloproteinases and Their Inhibitors: Potential for the Development of New Therapeutics.
    Raeeszadeh-Sarmazdeh M; Do LD; Hritz BG
    Cells; 2020 May; 9(5):. PubMed ID: 32466129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Matrix Metalloproteinases Inhibitors in Cancer Treatment: An Updated Review (2013-2023).
    Almutairi S; Kalloush HM; Manoon NA; Bardaweel SK
    Molecules; 2023 Jul; 28(14):. PubMed ID: 37513440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional mimetic peptide discovery isolated by phage display interacts selectively to fibronectin domain and inhibits gelatinase.
    Shoari A; Rasaee MJ; Kanavi MR; Daraei B
    J Cell Biochem; 2019 Dec; 120(12):19699-19711. PubMed ID: 31270859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential clinical applications of matrix metalloproteinase inhibitors and their future prospects.
    Li W; Saji S; Sato F; Noda M; Toi M
    Int J Biol Markers; 2013 Jun; 28(2):117-30. PubMed ID: 23787494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix Metalloproteinases (MMPs) in Targeted Drug Delivery: Synthesis of a Potent and Highly Selective Inhibitor against Matrix Metalloproteinase- 7.
    Wang LL; Zhang B; Zheng MH; Xie YZ; Wang CJ; Jin JY
    Curr Top Med Chem; 2020; 20(27):2459-2471. PubMed ID: 32703131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix Metalloproteinases: From Molecular Mechanisms to Physiology, Pathophysiology, and Pharmacology.
    de Almeida LGN; Thode H; Eslambolchi Y; Chopra S; Young D; Gill S; Devel L; Dufour A
    Pharmacol Rev; 2022 Jul; 74(3):712-768. PubMed ID: 35738680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs.
    Jabłońska-Trypuć A; Matejczyk M; Rosochacki S
    J Enzyme Inhib Med Chem; 2016; 31(sup1):177-183. PubMed ID: 27028474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of Action of Novel Drugs Targeting Angiogenesis-Promoting Matrix Metalloproteinases.
    Fields GB
    Front Immunol; 2019; 10():1278. PubMed ID: 31214203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there new hope for therapeutic matrix metalloproteinase inhibition?
    Vandenbroucke RE; Libert C
    Nat Rev Drug Discov; 2014 Dec; 13(12):904-27. PubMed ID: 25376097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix metalloproteinase contribution in management of cancer proliferation, metastasis and drug targeting.
    Abdel-Hamid NM; Abass SA
    Mol Biol Rep; 2021 Sep; 48(9):6525-6538. PubMed ID: 34379286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Implications of Compounds Designed to Inhibit ECM-Modifying Metalloproteinases.
    Amar S; Minond D; Fields GB
    Proteomics; 2017 Dec; 17(23-24):. PubMed ID: 28613012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based molecular insights into matrix metalloproteinase inhibitors in cancer treatments.
    Lin H; Xu P; Huang M
    Future Med Chem; 2022 Jan; 14(1):35-51. PubMed ID: 34779649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix metalloproteinase inhibitors: a patent review (2011 - 2013).
    Li NG; Tang YP; Duan JA; Shi ZH
    Expert Opin Ther Pat; 2014 Sep; 24(9):1039-52. PubMed ID: 25098768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A fragment-based exploration of diverse MMP-9 inhibitors through classification-dependent structural assessment.
    Baidya SK; Banerjee S; Ghosh B; Jha T; Adhikari N
    J Mol Graph Model; 2024 Jan; 126():108671. PubMed ID: 37976979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of MMP-9 and MMP-9 Inhibition in Different Types of Thyroid Carcinoma.
    Li Z; Wei J; Chen B; Wang Y; Yang S; Wu K; Meng X
    Molecules; 2023 Apr; 28(9):. PubMed ID: 37175113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.